Search

Author/Creator Nozza, S.

1. Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. (5th March 2016)

Authors:
Galli, Laura; Spagnuolo, Vincenzo; Bigoloni, Alba; D'Arminio Monforte, Antonella; Montella, Francesco; Antinori, Andrea; Di Biagio, Antonio; Rusconi, Stefano; Guaraldi, Giovanni; Di Giambenedetto, Simona; Borderi, Marco; Gibellini, Davide; Caramatti, Giada; Lazzarin, Adriano; Castagna, Antonella;...
Journal:
Journal of antimicrobial chemotherapy
Issue:
Volume 71:Number 6(2016:Jun.)
Page Start:
1637
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Dynamics of adaptive and innate immunity in patients treated during primary human immunodeficiency virus infection: results from Maraviroc in HIV Acute Infection (MAIN) randomized clinical trial. (September 2015)

Authors:
Ripa, M.; Pogliaghi, M.; Chiappetta, S.; Galli, L.; Pensieroso, S.; Cavarelli, M.; Scarlatti, G.; De Biasi, S.; Cossarizza, A.; De Battista, D.; Malnati, M.; Lazzarin, A.; Nozza, S.; Tambussi, G.
Journal:
Clinical microbiology and infection
Issue:
Volume 21:Number 9(2015:Sep.)
Page Start:
876.e1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. (January 2015)

Authors:
Gianotti, N.; Canducci, F.; Galli, L.; Cossarini, F.; Salpietro, S.; Poli, A.; Nozza, S.; Spagnuolo, V.; Clementi, M.; Sampaolo, M.; Ceresola, E.R.; Racca, S.; Lazzarin, A.; Castagna, A.
Journal:
Clinical microbiology and infection
Issue:
Volume 21:Number 1(2015:Jan.)
Page Start:
103.e7
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

4. Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. (April 2017)

Authors:
d'Arminio Monforte, A.; Andreoni, M.; Angarano, G.; Antinori, A.; Castelli, F.; Cauda, R.; Di Perri, G.; Galli, M.; Iardino, R.; Ippolito, G.; Lazzarin, A.; Perno, C.F.; von Schloesser, F.; Viale, P.; Castagna, A.; Ceccherini-Silberstein, F.; Cozzi-Lepri, A.; Girardi, E.; Lo Caputo, S.; Mussini, C.
Journal:
Clinical microbiology and infection
Issue:
Volume 23:Number 4(2017)
Page Start:
267.e1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

5. Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study. (May 2015)

Authors:
Nozza, S.; Galli, L.; Antinori, A.; Chiappetta, S.; Mazzotta, F.; Zaccarelli, M.; Ottou, S.; De Battista, D.; Pogliaghi, M.; Di Pietro, M.; Malnati, M.; Ripa, M.; Bonora, S.; Lazzarin, A.
Journal:
Clinical microbiology and infection
Issue:
Volume 21:Number 5(2015:May)
Page Start:
510.e1
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗